Monoclonal antibodies for the prevention of rabies: theory and clinical practice

References

• Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Dis. 2006;5(3):191–195.
   Web of Science ®Google Scholar
• Cohen DJ, Benvenistry AI, Cianci J, Hardy MA. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft rejection. Am J Kidney Dis. 1989;14(5 Suppl 2):19–27.
   Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–2195.
   PubMed Web of Science ®Google Scholar
• Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. Bio Drugs. 1998;10(5):397–422.
   Google Scholar
• Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc). 1999;35(12):935–946.
   Web of Science ®Google Scholar
• Storch GA. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics. 1998;102(3 Pt 1):648–651.
   Web of Science ®Google Scholar
• Ferrajoli A, O’Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther. 2001;1(6):1059–1065.
   Web of Science ®Google Scholar
• Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin’s lymphoma. Curr Pharm Biotechnol. 2001;2(4):341–349.
   Google Scholar
• Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol. 2004;1(1):39–43.
   PubMedGoogle Scholar
• Ohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007; 18(1):7–15.
   Web of Science ®Google Scholar
• Cingoz O. Ustekinumab. mAbs. 2009;1(3):216–221.
   Web of Science ®Google Scholar
• Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab. Drugs. 2012;72(9):1293–1298.
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002;2(6):327–343.
   PubMed Web of Science ®Google Scholar
• Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis. 2003;36(1):60–63.
   Web of Science ®Google Scholar
• Wilde H, Hemachudha T, Jackson AC. View point: management of human rabies. Trans R Soc Trop Med Hyg. 2008;102(10):979–982.
   Web of Science ®Google Scholar
• World Health Organization. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec. 2007;82:425–436.
   Google Scholar
• World Health Organization. Rabies Information System of the WHO Collaboration Centre for Rabies Surveillance and Research. What is rabies? Available on: http://www.who-rabies-bulletin.org/about_rabies/What_is_rabies.aspx. Accessed October 2, 2013.
   Google Scholar
• World Health Organization. Recommendations on Rabies Post-Exposure Treatment and the Correct Technique of Intradermal immunizationagainst Rabies. World Health Organization; 1996. Available from: http://www.who.int. Accessed on July 21, 2013.
   Google Scholar
• World Health Organization. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization. WHO, Geneva. 1996. Available from: http://whqlibdoc.who.int/hq/1996/WHO_EMC_ZOO_96.6.pdf. Accessed October 2, 2013.
   Google Scholar
• World Health Organization. State of the art of new vaccine research and development. Section 7. Zoonotic infections. Chapter 7.5. Rabies. Pages 88–90. WHO, Geneva. 2006. Available from: http://whqlibdoc.who.int/hq/2006/WHO_IVB_06.01_eng.pdf. Accessed October 2, 2013.
   Google Scholar
• Wilde H, Khawplod P, Hemachudha T, Sitprija V. Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis. 2002;34(4):477–480.
   Web of Science ®Google Scholar
• Gacouin A, Bourhy H, Renaud JC, Camus C, Suprin E, Thomas R. Human rabies despite post-exposure vaccination. Eur J Clin Microbiol Infect Dis. 1999;18(3):233–235.
   PubMed Web of Science ®Google Scholar
• Hemachudha T, Mitrabhakdi E, Wilde H, Vejabhuti A, Siripataravanit S, Kingnate D. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis. 1999;28(1):143–144.
   PubMed Web of Science ®Google Scholar
• Dietzschold B, Kao M, Zheng YM, et al. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A. 1992;89(15):7252–7256.
   Web of Science ®Google Scholar
• Dietzschold B. Antibody-mediated clearance of viruses from the mammalian central nervous system. Trends Microbiol. 1993;1(2):63–66.
   Google Scholar
• World Health Organization. Rabies fact sheet N 99. WHO, Geneva. Available from: http://www.who.int/mediacentre/factsheets/fs099/en/print.html. Cited May 18, 2007. Accessed October 2, 2013.
   Google Scholar
• Goldsby RA, Kindt TJ, Osborne BA, Kuby J. Immunology. 5th ed. New York: W.H. Freeman and Company; 1996.
   Google Scholar
• Khawplod P, Wilde H, Chomckey P, et al. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously? Vaccine. 1996;14(5):389–391.
   Web of Science ®Google Scholar
• Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. Passive immunity in the prevention of rabies. Lancet Infect Dis. 2012;12(5):397–407.
   PubMed Web of Science ®Google Scholar
• Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Review. Vaccine. 2009;27(6):G38–G46.
   Google Scholar
• Wilde H, Chomchey P, Prakongsri S, Puyaratabandhu P, Chutivongse S. Adverse effects of equine rabies immune globulin. Vaccine. 1989;7(1):10–11.
   PubMed Web of Science ®Google Scholar
• Muhamuda K, Madhusudana SN, Ravi V. Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin. 2007;3(5):192–195.
   Google Scholar
• Fernandes A, Kaundinya JO, Daftary G, Saxena L, Banerjee S, Pattnaik P. Chromatographic purification of equine immunoglobulin G F(ab’)2 from plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876(1):109–115.
   Google Scholar
• Cupo P, de Azevedo-Marques MM, Sarti W, Hering SE. Proposal of abolition of the skin sensitivity test before equine rabies immune globulin application. Rev Inst Med Trop Sao Paulo. 2001;43(1):51–53.
   Google Scholar
• Hanlon CA, DeMattos CA, DeMatto CC, et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in postexposure prophylaxis. Vaccine. 2001;19(28–29):3834–3842.
   Web of Science ®Google Scholar
• Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602–614.
   PubMed Web of Science ®Google Scholar
• Helmick CG, Johnstone C, Summer J, Winkler WG, Fager S. A clinical study of Merieux human rabies immune globulin. J Biol Stand. 1982;10(4):357–367.
   Google Scholar
• Grifols Therapeutics Inc. Rabies immune globulin (human): HyperRAB® S/D. Available from: http://www.talecris-pi.info/inserts/hyperrab.pdf. Cited Sep 2012. Accessed October 2, 2012.
   Google Scholar
• Sanofi Pasteur SA. Rabies immune globulin (human) USP, heat treated. Imogam® Rabies – HT. Available from: https://www.vaccineshoppe.com/image.cfm?doc_id=10902&image_type=product_pdf. Cited Dec 2005. Accessed October 2, 2012.
   Google Scholar
• Wilde H, Chomchey P, Prakongsri S, Punyaratabandhu P. Safety of equine rabies immune globulin. Lancet. 1987;2(8570):1275.
   Web of Science ®Google Scholar
• Motoi Y, Sato K, Hatta H, Morimoto K, Inoue S, Yamada A. Production of rabies neutralizing antibody in hen’s egg using a part of the G protein expressed in Escherichia coli. Vaccine. 2005;23(23):3026–3032.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu Q, Feng X, et al. Rabbit anti-rabies immunoglobulins production and evaluation. Trop Biomed. 2011;28(1):138–148.
   Web of Science ®Google Scholar
• Redwanel RM, Fahmy A, El Hanafy A, Abd El-Baky N, Sallam SM. Ovine anti-rabies antibody production and evaluation. Comp Immunol Microbiol Infect Dis. 2009;32(1):9–19.
   Web of Science ®Google Scholar
• World Health Organization. WHO consultation on a monoclonal antibody cocktail for rabies post exposure treatment. WHO, Geneva. May 23–24, 2002.
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibodies of predetermined specificity. Nature. 1975;256: 495–497.
   PubMed Web of Science ®Google Scholar
• Buelow R, van Schooten W. Ernst Schering Foundation symposium proceedings, Berlin, Germany: Springer-Verlag; 2007.
   Google Scholar
• Goldstein G; Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho multicenter transplant study group. N Engl J Med. 1985;313(6):337–342.
   Google Scholar
• Boenisch T. Antibodies. Chapter 1. Immunochemical Staining Methods. 5th ed. Carpinteria, CA: Dako North America; 2009.
   Google Scholar
• Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007;25(12):1421–1434.
   PubMed Web of Science ®Google Scholar
• Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J. 2006;8(2):E383–E390.
   Web of Science ®Google Scholar
• Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol. 2005;79(11):6644–6654.
   PubMed Web of Science ®Google Scholar
• Law M, Hangartner L. Antibodies against viruses: passive and active immunization. Curr Opin Immunol. 2008;20(4):486–492.
   Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703.
   PubMed Web of Science ®Google Scholar
• Flamand A, Wiktor TJ, Koprowski H. Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein. J Gen Virol. 1980;48(1):105–109.
   Google Scholar
• Lafon M, Ideler J, Wunner WH. Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies. Dev Biol Stand. 1984;57:219–225.
   Google Scholar
• Lafon M, Wiktor TJ, Macfarlan RI. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol. 1983;64(Pt 4):843–851.
   PubMedGoogle Scholar
• Nagarajan T, Reddy GS, Mohanasubramanian B, et al. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals. 2006;34(1):21–27.
   Web of Science ®Google Scholar
• Ni Y, Tominaga Y, Honda Y, Morimoto K, Sakamoto S, Kawai A. Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719. Microbiol Immunol. 1995;39(9):693–702.
   Web of Science ®Google Scholar
• Prehaud C, Coulon P, Lafay F, Thiers C, Flamand A. Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol. 1988;62(1):1–7.
   PubMed Web of Science ®Google Scholar
• Schumacher CL, Dietzschold B, Ertl HCJ, Hong-Shun N, Rupprecht CE, Koprowski H. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest. 1989;84(3):971–975.
   Web of Science ®Google Scholar
• Seif I, Coulon P, Rollin PE, Flamand A. Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J Virol. 1985;53(3):926–934.
   PubMed Web of Science ®Google Scholar
• Wiktor TJ, Koprowski H. Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci U S A. 1978;75(8):3938–3942.
   Web of Science ®Google Scholar
• Benmansour A, Leblois H, Coulon P, et al. Antigenicity of rabies virus glycoprotein. J Virol. 1991;65(8):4198–4203.
   PubMed Web of Science ®Google Scholar
• Dietzschold B, Gore M, Casali P, et al. Biological characterization of human monoclonal antibodies to rabies virus. J Virol. 1990;64(6):3087–3090.
   PubMed Web of Science ®Google Scholar
• Lafon M, Edelman L, Bouvet JP, et al. Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol. 1990;71(8):1689–1696.
   Google Scholar
• Walker PJ, Kongsuwan K. Deduced structural model for animal rhabdovirus glycoproteins. J Gen Virol. 1999;80:1211–1220.
   Web of Science ®Google Scholar
• Kuzmina NA, Kuzmin IV, Ellison JA, Rupprecht CE. Conservation of binding epitopes for monoclonal antibodies on the rabies virus glycoprotein. J Antivir Antiretrovir. 2013;5(2):37–43.
   Google Scholar
• Montano-Hirose JA, Lafage M, Weber P, Badrane H, Tordo N, Lafon M. Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice. Vaccine. 1993;11(12):1259–1266.
   Web of Science ®Google Scholar
• Goudsmit J, Marissen WE, Weldon WC, et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis. 2006;193(6):796–801.
   PubMed Web of Science ®Google Scholar
• Muller T, Dietzschold B, Ertl H, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis. 2009;3(11):1–10.
   Web of Science ®Google Scholar
• Wang Y, Rowley KJ, Booth BJ, Sloan SE, Ambrosino DM, Babcock GJ. G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates. Antiviral Res. 2011;91(2):187–194.
   Web of Science ®Google Scholar
• Badger CC, Anasetti C, Davis J, Bernstein ID. Treatment of malignancy with unmodified antibody. Pathol Immunopathol Res. 1987;6(5–6):419–434.
   Google Scholar
• Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol. 1994;15(1):42–52.
   Web of Science ®Google Scholar
• Both L, van Dolleweerd C, Wright E, et al. Production, characterization, antigenic specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB J. 2013;27(5):2055–2065.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. mAbs. 2010;2(3):256–265.
   PubMed Web of Science ®Google Scholar
• Winter G, Milstein C. Man-made antibodies. Nature. 1991;349(6307):293–299.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuichi Y, Ide T, Goto M. Incorrect use of “immortalization” for B-lymphoblastoid cell lines transformed by Epstein-Barr virus. J Virol. 1999;73(11):9690–9691.
   Web of Science ®Google Scholar
• Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. 2007;25(10):1134–1143.
   PubMed Web of Science ®Google Scholar
• Nagarajan T, Rupprecht CE, Dessain SK, Rangarajan PN, Thiagarajan D, Srinivasan VA. Human monoclonal antibody and vaccine approaches to prevent human rabies. Curr Top Microbiol Immunol. 2008; 317: 67–101.
   Web of Science ®Google Scholar
• Matsumoto T, Yamada K, Noguchi K, et al. Isolation and characterization of novel human monoclonal antibodies possessing neutralizing ability against rabies virus. Microbiol Immunol. 2010;54(11):673–683.
   Web of Science ®Google Scholar
• Jones DH, Kross N, Anema R, et al. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol Prog. 2003;19(1):163–168.
   PubMed Web of Science ®Google Scholar
• Champion JM, Kean RB, Rupprecht CE, et al. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods. 2000;235(1–2):81–90.
   Web of Science ®Google Scholar
• Bakker AB, Marissen WE, Kramer RA, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol. 2005;79(14):9062–9068.
   Web of Science ®Google Scholar
• Sloan SE, Hanlon C, Weldon W, et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine. 2007;25(15):2800–2810.
   PubMed Web of Science ®Google Scholar
• de Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med. 2007;58:359–368.
   Web of Science ®Google Scholar
• Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol. 2008;20(4):460–470.
   PubMed Web of Science ®Google Scholar
• McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990;348(6301):552–554.
   PubMed Web of Science ®Google Scholar
• Huston JS, Levinson D, Mudgett Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988;85(16):5879–5883.
   PubMed Web of Science ®Google Scholar
• Zhao XL, Yin J, Chen WQ, Jiang M, Yang G, Yang ZH. Generation and characterization of human monoclonal antibodies to G5, a linear neutralization epitope on glycoprotein of rabies virus, by phage display technology. Microbiol Immunol. 2008;52(2):89–93.
   Web of Science ®Google Scholar
• Zhao XL, Chen WQ, Yang ZH, Li JM, Zhang SJ, Tian LF. Selection and affinity maturation of human antibodies against rabies virus from a scFv gene library using ribosome display. J Biotechnol. 2009;144(4):253–258.
   Web of Science ®Google Scholar
• Liu X, Lin H, Tang Q, et al. Characterization of human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine. PLoS One. 2011;6(5):1–8.
   Web of Science ®Google Scholar
• Li C, Zhang F, Lin H, et al. Generation and characterization of the human neutralizing antibody fragment Fab019 against rabies virus. Acta Pharmacol Sin. 2011;32(3):329–337.
   Web of Science ®Google Scholar
• Raag R, Whitlow M. Single chain Fvs. FASEB J. 1995;9(1):73–80.
   Web of Science ®Google Scholar
• Duan Y, Gu TJ, Jiang CL, et al. A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency. Mol Immunol. 2012;51(2):188–196.
   Web of Science ®Google Scholar
• Wang DD, Su MM, Sun Y, Huang SL, Wang J, Yan WQ. Expression, purification and characterization of a human single-chain Fv antibody fragment fused with the Fc of an IgG1 targeting a rabies antigen in Pichia pastoris. Protein Expr Purif. 2012;86(1):75–81.
   Web of Science ®Google Scholar
• Repp R, Kellner C, Muskulus A, et al. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods. 2011;373(1–2):67–78.
   Web of Science ®Google Scholar
• Palmberger D, Rendic D, Tauber P, Krammer F, Wilson IBH, Grabherr R. Insect cells for antibody production: evaluation of an efficient alternative. J Biotechnol. 2011;153(3–4):160–166.
   Web of Science ®Google Scholar
• Chadd HE, Chamow SM. Therapeutic antibody expression technology. Curr Opin Biotechnol. 2001;12(2):188–194.
   PubMed Web of Science ®Google Scholar
• de Kruif J, Kramer A, Nijhuis R, et al. Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng. 2010;106(5):741–750.
   Web of Science ®Google Scholar
• Jones DH, van Berkel PHC, Logtenberg T, Bout A. PER.C6 cell-line for human antibody production. Genetic Eng News. 2002;22(10):50.
   Google Scholar
• Barnard GC, Kull AR, Sharkey NS, et al. High-throughput screening and selection of yeast cell lines expressing monoclonal antibodies. J Ind Microbiol Biotechnol. 2010;37(9):961–971.
   Web of Science ®Google Scholar
• Ko K, Tekoah, Y, Rudd PM, et al. Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A. 2003;100(13):8013–8018.
   PubMed Web of Science ®Google Scholar
• Tran M, Zhou B, Pettersson PL, Gonzalez MJ, Mayfield SP. Synthesis and assembly of a full length human monoclonal antibody in algal chloroplasts. Biotechnol Bioeng. 2009;104(4):663–673.
   PubMed Web of Science ®Google Scholar
• Pollock DP, Kutzko JP, Birck-Wilson E, et al. Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods. 1999;231(1–2):147–157.
   PubMed Web of Science ®Google Scholar
• Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol. 2002;13(2):117–123.
   PubMed Web of Science ®Google Scholar
• Sabourin M, Huang Y, Dhulipala P, et al. Increasing antibody yield and modulating final product quality using the Freedom™ CHO-S™ production platform. BMC Proc. 2011;5(8):P102.
   Google Scholar
• Wurm F, Hacker D. First CHO genome. Nat Biotechnol. 2011;29(8):718–720.
   PubMed Web of Science ®Google Scholar
• Bailey LA, Hatton D, Field R, Dickson AJ. Determination of Chinese hamster ovary cell line stability and recombinant antibody expression during long-term culture. Biotechnol Bioeng. 2012;109(8):2093–2103.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Schnell MJ, Pulmanausahakul R, et al. High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods. 2001;252(1–2):199–206.
   Web of Science ®Google Scholar
• Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus neutralizing monoclonal antibodies for post exposure prophylaxis of rabies. J Infect Dis. 2003;187:53–56.
   Google Scholar
• Paul M, Dolleweerd CV, Drake PMW, et al. Molecular pharming: future targets and aspirations. Human Vaccin. 2011;7(3):375–382.
   PubMed Web of Science ®Google Scholar
• Fan JY, Shen Z, Wang G, et al. Secretory expression of human scFv against keratin in Pichia pastoris and its effects on cultured keratinocytes. Arch Dermatol Res. 2009;301(5):367–372.
   Web of Science ®Google Scholar
• Rainer F, Jurgen D, Neil E, et al. Towards molecular farming in the future: Pichia pastoris-based production of single-chain antibody fragments. Biotechnol Appl Biochem. 1999;30(Pt 2):117–120.
   Google Scholar
• US National Institutes of Health. Learn about clinical studies. Available from: http://clinicaltrials.gov/ct2/about-studies/learn. Cited Aug 2012. Accessed October 2, 2013.
   Google Scholar
• US National Institutes of Health. Glossary definition. Available from: http://clinicaltrials.gov/ct2/help/glossary/phase. Accessed October 2, 2013.
   Google Scholar
• Gogtay N, Thatte U, Kshirsagar N, et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012;30(50):7315–7320.
   PubMed Web of Science ®Google Scholar
• Shelton ML. Clinical trial for rabies monoclonal antibody. Available from: http://www.eurekalert.org/pub_releases/2012–2008/uomm-ctf080712.php. Cited August 7, 2012. Accessed October 2, 2013.
   Google Scholar
• Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability and neutralizing activity. Vaccine. 2008;26(47):5922–5927.
   PubMed Web of Science ®Google Scholar
• Crucell Holland BV. Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents. Available from: http://clinicaltrials.gov/show/NCT00708084. Accessed October 21, 2013.
   Google Scholar
• Crucell Holland BV. A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects. Available from: http://clinicaltrials.gov/show/NCT00656097. Accessed October 21, 2013.
   Google Scholar
• Crucell Holland BV. Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults. Available from: http://clinicaltrials.gov/show/NCT01228383. Accessed October 21, 2013.
   Google Scholar
• Serum Institute of India Ltd. A clinical trial to assess the safety and rabies antibody levels in blood following a new Human Monoclonal Antibody to Rabies (SII RMab) in comparison with Human Rabies Immune Globulin, when given together with Rabies Vaccine (RABIVAX®) in healthy adults. Available from: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=680. Accessed October 21, 2013.
   Google Scholar
• Marissen WE, Kramer A, Rice A, et al. Novel Rabies Virus-Neutralizing Epitope Recognized by Human Monoclonal Antibody: Fine Mapping and Escape Mutant Analysis. J. Virol. 2005;79(8):4672–4678.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Expert Consultation on Rabies, Second report. WHO Techinical Report Series 982. Available from: http://apps.who.int/iris/bitstream/10665/85346/1/9789241209823_eng.pdf. Accessed November 28, 2013.
   Google Scholar